• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
159154 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  7 s! [( V1 s; q. a4 n: d7 A$ e

1 }# _; h% Y7 f2 G) ]
8 M. R! K9 Z: D$ \* N9 f  SSub-category:
& z( S- s# d9 aMolecular Targets
6 o/ l$ {: {2 c
" f; a0 L! J; \3 y9 V6 }% d- L# q( L, [* {# e: @
Category:7 v  o( \( V: g$ w
Tumor Biology
# L! r& Y* R1 n4 |6 ]7 B! n  I
. Z: M" r( O* K5 c; u* \9 c, s* c# H" g( U# l' Q. \# r9 B2 m5 g" _
Meeting:
6 }# a0 j3 a. q! @( [# h  S# j2011 ASCO Annual Meeting
' u6 ]( G) K0 W* Y
, P3 t, u4 L8 o6 k  ]5 k! Q3 z0 N9 H, ^/ o6 _  s
Session Type and Session Title:
8 l7 m, V5 Q. A' y; z3 k2 c! S2 YPoster Discussion Session, Tumor Biology
! x5 j9 N8 n, F$ m5 m5 }8 f
  h3 T; q/ M1 N  ]; M6 ^8 L, I9 e' z) U2 g& c7 q1 x
Abstract No:
! p4 K1 F4 }, P( [  R" K, A* g* q10517 , \; A& V- V$ k
: `2 K  _9 w# u
7 h9 j7 w  n; F: ]8 l- _- K
Citation:
6 J) {* w2 d+ G* l9 o. aJ Clin Oncol 29: 2011 (suppl; abstr 10517) 3 W. U: R- {. r' Z, C9 F

4 G. `+ j3 O  \- ?& Z! a$ A! Z& ?4 r% m
Author(s):
. U& @: X  Q' QJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China - N# w( A! U- R
% c0 ~6 O) @. K" d. [  z
$ `0 j0 F' U9 s( S. I$ M& u

: h# G" M0 F+ K2 F# ZAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
+ b8 ~  Y7 g* _3 L$ u0 `6 h9 ^" h( r. i
Abstract Disclosures
9 }+ {* o9 w6 t$ u3 h& y  X' C7 p: w# \- f3 D
Abstract:
! r! e; q9 b. e% S+ I2 A+ T( p" G+ I) @( A7 N
3 {+ N9 N( A  E4 A
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
8 m1 c# w7 P2 E7 e" V) `
- v; q7 k3 t3 I: g' z   }! P9 \. Z2 w% X; u. O
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
/ Z' o0 U4 V8 C0 S' ]* A没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

$ E+ d2 ^! [/ \* w9 Q化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
& K5 G3 C' k5 Y- |: _易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。/ S" x/ l: t. I4 t
ALK一个指标医院要900多 ...
* s7 i  }( x2 M; w
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?1 t4 s% O  \8 Q% |

: n* K  ^7 l6 P5 W现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表